EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC 4.0

Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective

Micaela B Reddy iD, Tamara D Cabalu, Loeckie de Zwart iD, Diane Ramsden iD, Martin E Dowty iD, Kunal S Taskar iD, Justine Badée, Jayaprakasam Bolleddula iD, Laurent Boulu, Qiang Fu iD, Masakatsu Kotsuma, Alix F Leblanc iD and 10 more

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3477 ↗

At a glance

Übersichtsarbeit in Clinical Pharmacology & Therapeutics, 2025. Written by Micaela B Reddy and 21 co-authors. Institution: Clinical Pharmacology, Oncology, Pfizer Inc., Boulder, Colorado, USA. Major MEDLINE topics: Rifampin, Cytochrome P-450 CYP3A, Cytochrome P-450 CYP3A Inducers, Models, Biological. Cited 12 times so far (Crossref); 87 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Physiologically‐based pharmacokinetic (PBPK) modeling offers a viable approach to predict induction drug–drug interactions (DDIs) with the potential to streamline or reduce clinical trial burden if predictions can be made with sufficient confidence. In the current work, the ability to predict the effect of rifampin, a well‐characterized strong CYP3A4 inducer, on 20 CYP3A probes with publicly available PBPK models (often developed using a workflow with optimization following a strong inhibitor DDI study to gain confidence in fraction metabolized by CYP3A4, f m,CYP3A4 , and fraction available after intestinal metabolism, Fg), was assessed. Substrates with a range of f m,CYP3A4 (0.086–1.0), Fg (0.11–1.0) and hepatic availability (0.09–0.96) were included. Predictions were most often accurate for compounds that are not P‐gp substrates or that are P‐gp substrates but that have high permeability. Case studies for three challenging DDI predictions (i.e., for eliglustat, tofacitinib, and ribociclib) are presented. Along with parameter sensitivity analysis to understand key parameters impacting DDI simulations, alternative model structures should be considered, for example, a mechanistic absorption model instead of a first‐order absorption model might be more appropriate for a P‐gp substrate with low permeability. Any mechanisms pertinent to the CYP3A substrate that rifampin might impact (e.g., induction of other enzymes or P‐gp) should be considered for inclusion in the model. PBPK modeling was shown to be an effective tool to predict induction DDIs with rifampin for CYP3A substrates with limited mechanistic complications, increasing confidence in the rifampin model. While this analysis focused on rifampin, the learnings may apply to other inducers.

Subjects

MeSH terms (MEDLINE)

RifampinCytochrome P-450 CYP3ACytochrome P-450 CYP3A InducersModels, BiologicalHumansDrug Interactions

Substances

RifampinCytochrome P-450 CYP3ACytochrome P-450 CYP3A InducersCYP3A4 protein, human

Authors and institutions

  • Clinical Pharmacology, Oncology, Pfizer Inc., Boulder, Colorado, USA.
  • DMPK, Pharmacokinetics, Dynamics, Metabolism, and Bioanalytics, Merck & Co., Inc., Rahway, New Jersey, USA.
  • DMPK, Janssen Pharmaceutica NV, A Johnson & Johnson Company, Beerse, Belgium.
  • DMPK, Research and Early Development, Oncology R&D, AstraZeneca, Boston, Massachusetts, USA.
  • Pharmacokinetics Dynamics and Metabolism, Pfizer Inc, Cambridge, Massachusetts, USA.
  • DMPK, Pre-Clinical Sciences, Research Technologies, GSK, Stevenage, UK.

ORCID profiles: Micaela B Reddy, Loeckie de Zwart, Diane Ramsden, Martin E Dowty, Kunal S Taskar, Jayaprakasam Bolleddula, Qiang Fu, Alix F Leblanc, Gareth Lewis, Neil Parrott, Venkatesh Pilla Reddy, Chandra Prakash, Kushal Shah, Dwaipayan Mukherjee, Jessica Rehmel, Niresh Hariparsad

Cite

APA

Reddy, M. B., Cabalu, T. D., de Zwart, L., Ramsden, D., Dowty, M. E., Taskar, K. S., Badée, J., Bolleddula, J., Boulu, L., Fu, Q., Kotsuma, M., Leblanc, A. F., Lewis, G., Liang, G., Parrott, N., Pilla Reddy, V., Prakash, C., Shah, K., Umehara, K., …, & Hariparsad, N. (2025). Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3477

Vancouver

Reddy MB, Cabalu TD, de Zwart L, Ramsden D, Dowty ME, Taskar KS, et al. Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3477

BibTeX
@article{Reddy2025,
  author = {Reddy, Micaela B and Cabalu, Tamara D and de Zwart, Loeckie and Ramsden, Diane and Dowty, Martin E and Taskar, Kunal S and Badée, Justine and Bolleddula, Jayaprakasam and Boulu, Laurent and Fu, Qiang and Kotsuma, Masakatsu and Leblanc, Alix F and Lewis, Gareth and Liang, Guiqing and Parrott, Neil and Pilla Reddy, Venkatesh and Prakash, Chandra and Shah, Kushal and Umehara, Kenichi and Mukherjee, Dwaipayan and Rehmel, Jessica and Hariparsad, Niresh},
  title = {Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3477}
}
Start for free →